2024
DOI: 10.1007/s40262-024-01355-6
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Pharmacokinetics and Pharmacodynamics of Naloxone

Teijo I. Saari,
John Strang,
Ola Dale

Abstract: Naloxone is a World Health Organization (WHO)-listed essential medicine and is the first choice for treating the respiratory depression of opioids, also by lay-people witnessing an opioid overdose. Naloxone acts by competitive displacement of opioid agonists at the μ-opioid receptor (MOR). Its effect depends on pharmacological characteristics of the opioid agonist, such as dissociation rate from the MOR receptor and constitution of the victim. Aim of treatment is a balancing act between restoration of respirat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 150 publications
0
1
0
Order By: Relevance
“…40 Also, real-world data from take-home naloxone programs is limited because it doesn’t track what happens with every dispensed naloxone dose. 41,42 This highlights the importance of developing dual-action TDM microsystems, as discussed in this study.…”
Section: Resultsmentioning
confidence: 79%
“…40 Also, real-world data from take-home naloxone programs is limited because it doesn’t track what happens with every dispensed naloxone dose. 41,42 This highlights the importance of developing dual-action TDM microsystems, as discussed in this study.…”
Section: Resultsmentioning
confidence: 79%